MeDALL – Mechanisms of the Development of Allergy
Project reference: 261357
Funded under: FP7-HEALTH and managed by CNRS
From 2010-12-01 to 2015-05-31, closed project
MeDALL advanced the state-of-the-art knowledge in the mechanisms underlying the epidemic of IgE-associated allergic diseases. It was based on previous EU projects such as U-BIOPRED which have helped to design this innovative integrated research strategy. It aimed at providing new insights in epigenetics, biomarkers and immunologic mechanisms.
- Define the different allergic/atopic phenotypes.
- Provide novel insight in the individual susceptibility to develop IgE-associated allergic diseases.
- Provide novel predictive diagnosis of allergy (before it has started or at early stages).
- Open novel avenues for the prevention of allergy.
Allergy phenotype handprints developed through an integrative systems biology approach (adapted from U-BIOPRED).
Through the lead of the MeDALL Knowledge management, bioinformatics, transcriptomics and systems biology for allergy biomarker discovery workpackage the main tasks for the EISBM team have been to:
- Establish the knowledge management and bioinformatics infrastructure necessary to achieve MeDALL objectives in relation with U-BIOPRED.
- Perform unbiased discovery of allergy phenotype biomarkers of severe asthma in birth cohorts using transcriptomics fingerprints and integrated network phenotype handprints.
- Validate the fingerprints and handprints in birth cohort follow-up for disease progression, therapeutic interventions, and for improvement of human and animal models.
The MeDALL consortium consists of 23 institutions from academia and industry with experts in the fields of epidemiology, genetics, immunology, biology, animal models, biochemistry and systems biology.
Charles AuffrayEISBM President and Founding Director
EISBM past contributors
- Stéphane Ballereau
- Camille Ménard
- Stéphane Joly
- Nathanaël Lemonnier